Table 5.

Outcomes of Participants (n=145) with Specific Non- Acetaminophen Diagnoses

	Adduct Positive n=8	Adduct Negative n=137	P
	n(%)	n(%)
Hepatic Encephalopathy at Enrollment*			0.25
Grade II or less	6(75)	117(89)
Grade III or IV	2(25)	15(11)
Maximum Hepatic Encephalopathy**			1.00
Grade II or less	6(75)	104(81)
Grade III or IV	2(25)	25(19)
Laboratory Value Median (Q1–Q3)
Alanine Aminotransferase IU/L	2592 (1402–5945)	638 (113–2121)	0.007
Aspartate Aminotransferase IU/L	3461 (686–6090)	911 (214–2717)	0.04
Total Bilirubin mg/dL	2.6 (1.2–6.0)	9.2 (4.2–18.0)	0.01
Direct Bilirubin mg/dL	1.4 (0.7–2.0)	4.9 (2.0–12.4)	0.01
International Normalized Ratio	2.7 (2.0–4.1)	2.5 (2.1–3.3)	0.63
Creatinine mg/dL	0.7 (0.3–2.2)	0.5 (0.3–0.7)	0.62
21 day Outcome			0.87
Death without Transplantation	1(13)	22(16)
Transplantation	1(13)	31(23)
Spontaneous Survival	6(75)	84(61)

^*5 participants with unknown encephalopathy in negative group

^**8 participants with unknown maximal encephalopathy in negative group